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Ciprofloxacin resistance was analyzed in 354 Campylo-
bacter jejuni isolates collected during two study periods (1995–
1997 and 1998–2000) from travelers returning to Finland. The
increase in resistance between the two periods was significant
among all isolates (40% vs. 60%; p<0.01), as well as among
those from Asia alone (45% vs. 72%; p<0.01).
ampylobacter jejuni isolates are naturally susceptible to
fluoroquinolones (1,2). During the 1990s, however, fluo-
roquinolone resistance in Campylobacter rapidly increased in
several countries (3). In Thailand and Spain, for example, up
to 80% of Campylobacter isolates are fluoroquinolone-resis-
tant (4,5). However, major differences in Campylobacter fluo-
roquinolone resistance levels are known to occur, and in many
parts of the world fluoroquinolone resistance levels remain
low (3). This study was performed to evaluate the level of flu-
oroquinolone resistance in C. jejuni isolates from travelers
returning to Finland and to specify the countries where resis-
tant isolates are acquired. 
The Study 
Our study included 354 clinical human fecal C. jejuni iso-
lates collected from travelers returning to Finland from 1995
to 2000. The isolates were collected in two different phases
from the laboratory of a large private hospital in Helsinki, Fin-
land. Participants were treated as outpatients, and no data on
antimicrobial usage before fecal sampling were available; all
participants had a history of traveling abroad within the pre-
ceding 2 weeks. From January 1995 to November 1997, we
consecutively collected 205 isolates, and from October 1998
to January 2000, 149 isolates. The isolates were cultured and
identified by standard microbiologic methods (6). MICs of
ciprofloxacin and nalidixic acid for the isolates were deter-
mined by the agar plate dilution method, as described (7). C.
jejuni RH 3583 (a local control strain, originally isolated in
Edinburgh, U.K., C. jejuni 143483) was used as a control in
susceptibility testing and also as a growth control strain. The
MIC breakpoint used for the resistance to ciprofloxacin was
that recommended by the National Committee for Clinical
Laboratory Standards (NCCLS) for non-Enterobacteriaceae
(8). To nalidixic acid, the breakpoints were those recom-
mended by NCCLS for Enterobacteriaceae (8).
Data concerning the numbers of travels from Finland to
countries of interest (i.e., countries with the largest numbers of
all C. jejuni isolates or of ciprofloxacin-resistant isolates) dur-
ing the study months were received from Statistics Finland
(available from: URL: www.stat.fi/). The susceptibility data
were analyzed by using the WHONET5 computer program
(available from: URL: www.who.int/emcWHONET/WHO-
NET.html).
Statistical analysis was made by using the chi-square test
and the Fisher exact test. Differences between C. jejuni infec-
tion rates in travelers returning from various travel destina-
tions were statistically tested with Poisson regression analysis.
Differences were quantified with infection rates and 95% con-
fidence intervals; p values of <0.05 were considered signifi-
cant. Statistical data were analyzed by using the SAS system
for Windows, release 8.2/2001 (SAS Institute, Inc., Cary, NC).
Of the 354 C. jejuni isolates studied, the country where
campylobacteriosis was acquired could be identified for 319
isolates, collected from travelers to 40 different countries. The
origin of 22 isolates was traced at least to a continental level;
the patients involved had several travel destinations. The ori-
gin of 13 isolates remained unknown. The most common
countries of origin were Spain with 77 (22%) isolates, Thai-
land with 50 (14%) isolates, and India with 23 (6%) isolates.
During the first study period (1995–1997), 205 isolates were
collected from travelers. Of the 34 countries of origin that
were identified, the most common were Spain with 40 (20%)
isolates, India with 19 (9%) isolates, and Thailand and Turkey,
both with 17 (8%) isolates. During the second study period
(1998–2000), 149 isolates were collected from travelers; of the
25 countries of origin identified, the most common were Spain
with 37 (25%) isolates, Thailand with 33 (22%) isolates, and
Portugal and Tunisia, both with 6 (4%) isolates.
Of all 354 C. jejuni isolates, 172 (49%) were resistant to
ciprofloxacin. Of the 205 isolates collected in 1995–1997, 82
(40%) were resistant to ciprofloxacin compared with 90 (60%)
of the 149 isolates collected in 1998–2000 (p<0.01). When
analyzed by continent, the increase in fluoroquinolone resis-
tance between these two periods was significant among the
isolates from Asia alone (45% vs. 72%, p<0.01; Table 1). An
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increasing tendency for fluoroquinolone resistance was also
observed in the isolates from the three additional continents.
The numbers and proportions of ciprofloxacin-resistant iso-
lates collected from travelers returning from Spain and Thai-
land, the two most common countries of origin, were analyzed
separately. During the first and second collection periods, the
respective numbers and proportions of ciprofloxacin-resistant
isolates were 29 (73%) and 26 (70%) in the isolates from
Spain, and 13 (77%) and 26 (79%) in the isolates from Thai-
land. To assess whether the larger proportion of isolates from
Thailand during the second period (8% vs. 22%) explained the
significant increase in fluoroquinolone resistance in the whole
study group, we analyzed the data excluding all isolates from
Thailand. The increase in ciprofloxacin resistance, from 37%
to 55%, was still significant (p<0.01). A corresponding analy-
sis that excluded all isolates from both Spain and Thailand
resulted in an increase in ciprofloxacin resistance from 27% to
48% (p<0.01).
The number of ciprofloxacin-resistant C. jejuni isolates
collected was compared with the estimated numbers of all trips
from Finland during the study period to the five most frequent
countries of origin for the ciprofloxacin-resistant isolates.
These speculative infection rates were used to calculate rate
ratios between these countries. Because the speculative infec-
tion rate by fluoroquinolone-resistant C. jejuni isolates was
highest in travelers returning from Thailand, that country was
used as the reference in the rate ratio comparisons. The rate
ratios by fluoroquinolone-resistant isolates in travelers return-
ing from Spain and Portugal were 0.11 in both groups; the dif-
ferences were statistically significant compared with the ratios
for the reference country (p<0.01 for both; Table 2). The corre-
sponding rate ratios  in travelers returning from India and
China were 0.90 and 0.72, respectively; these differences were
not significant.
Conclusions
We have shown that ciprofloxacin resistance significantly
increased (from 40% to 60%; p<0.01) during the study period
among all C. jejuni isolates from travelers. The increase was
also significant in isolates from Asia alone, suggesting a con-
tinual presence of selection pressure for the emergence of fluo-
roquinolone resistance on that continent. Moreover, an
 Table 1. Origin of 354 Campylobacter jejuni isolates from travelers returning to Finland and proportion of ciprofloxacin-resistant isolates during 
two collection periods
Geographic area
1995–1997 1998–2000
All isolates % Ciprofloxacin resistant All isolates % Ciprofloxacin resistant
Africa 24 17 8 38
America 4 0 3 67
Asia 78 45a 57 72a
Southeast Asia 28 61 39 77
Other areas 50 36 18 61
Europe 93 44 73 51
Mediterranean area 64 59 48 69
Other areas 29 10 25 16
Total 205b 40a 149c 60a
aDifference is statistically significant (p<0.01).
bOne isolate from Australia and five isolates of unknown origin included.
cEight isolates of unknown origin included.
Table 2. Rate ratios of travel-associated infections with ciprofloxacin-resistant Campylobacter jejuni isolatesa
Country
Estimated no. of trips 
from Finland during
 the study monthsb
No. of all 
isolates
Speculative 
infection ratec Rate ratiod
No. of 
ciprofloxacin-
resistant isolates
Speculative infection 
ratec by ciprofloxacin-
resistant isolates
Rate ratiod by 
ciprofloxacin-
resistant isolates
Spain (incl. 
Canary Islands)
1,145,872 77 (0.1) 0.12 (0.08 to 0.17) 55 (0.05) 0.11 (0.07 to 0.16)e
Thailand 87,842 50 (0.6) 1 39 (0.44) 1e
India 27,591 23 (0.8) 1.46 (0.89 to 2.40) 11 (0.40) 0.90 (0.46 to 1.75)
China 25,073 12 (0.5) 0.84 (0.45 to 1.58) 8 (0.32) 0.72 (0.34 to 1.54)
Portugal 148,647 11 (0.1) 0.13 (0.07 to 0.25) 7 (0.05) 0.11 (0.05 to 0.24)e
aThe five most frequent countries of origin of ciprofloxacin-resistant C. jejuni isolates were included in this analysis.
bBased on the numbers of Finnish travelers to these countries; data collected from the reports of Statistics Finland.
cInfections per 1,000 trips. Since the total number of isolates from Finnish population was not studied, the rate is speculative but could be used to calculate comparable rate ratios.
dThailand as the reference country; 95% confidence intervals in parentheses.
eDifferences between Thailand and Spain, and Thailand and Portugal, are statistically significant (p<0.01).Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 269
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increasing tendency in ciprofloxacin resistance was observed
in isolates from three additional continents, but either the
increase (from 44% to 51% in Europe) or the number of iso-
lates (7 isolates from America and 32 isolates from Africa)
was small, and the changes were not statistically significant.
Throughout the study, the rates of ciprofloxacin resistance
remained on a high level in Spain and Thailand, the two most
frequent countries of origin for all foreign isolates, as well as
for resistant isolates. The fact that the increase in ciprofloxacin
resistance remained significant even after all isolates from
Spain and Thailand were excluded from the analysis illustrates
that the emergence and spread of fluoroquinolone-resistant C.
jejuni are not restricted to a few highly Campylobacter-
endemic countries. Rather, these findings show that C. jejuni
fluoroquinolone resistance, which manifested at the beginning
of the 1990s, continues to grow rapidly in many parts of the
world.
Several studies have focused on the quinolone resistance
of Campylobacter spp. In Spain, a rapid increase in quinolone
resistance was observed after 1988, with up to 50% of C.
jejuni isolates resistant by 1991 (9,10). In recent years, fluoro-
quinolone resistance rates among Spanish C. jejuni isolates
have been reported to reach 80% (5); these findings are in
accordance with the 70% to 73% resistance rates we observed
in isolates from Spain. Similarly, the 77% to 79% rates of
ciprofloxacin resistance among our isolates from Thailand
concur with the surveillance data, indicating that fluoroqui-
nolone resistance rates already exceed 80% in Thailand (4).
Our study provides data on C. jejuni fluoroquinolone resis-
tance in 40 countries and on four continents, rendering possi-
ble the evaluation of the relative risk for a Finnish traveler to
acquire an infection by ciprofloxacin-resistant C. jejuni in dif-
ferent travel destinations. When assessing the actual infection
rate by ciprofloxacin-resistant C. jejuni in any destination, the
number of ciprofloxacin-resistant C. jejuni isolates imported
from that destination during the study months should be
divided by the number of simultaneous trips from Finland. In
our study, the total number of resistant C. jejuni isolates
imported to Finland was not known, since we examined iso-
lates from one hospital only. Thus, when the numbers of cipro-
floxacin-resistant C. jejuni isolates identified were divided by
the simultaneous numbers of trips from the whole country, the
figures (referred to as speculative infection rates in Table 2)
did not provide any real data on infection rates by resistant iso-
lates. Nevertheless, these figures could be used to calculate
rate ratios between different travel destinations. Despite the
high proportions of ciprofloxacin-resistant isolates in Spain
(71%) and Portugal (64%), the risk of acquiring fluoroqui-
nolone-resistant campylobacteriosis appeared to be 10 times
smaller in those countries than in Thailand. These results are
in line with our previous results, which showed that a tourist’s
risk of acquiring quinolone-resistant salmonellosis was signifi-
cantly higher in Thailand and Malaysia than in other travel
destinations (11). 
In conclusion, we demonstrated a significant increase in
ciprofloxacin resistance among all C. jejuni travelers’ isolates,
as well as among the isolates from Asia alone. The rate of
ciprofloxacin resistance remained on a high level throughout
the study in Spain and Thailand, the two most frequent coun-
tries of origin of the ciprofloxacin-resistant isolates. These
data support the concept of continuous selection pressure for
the emergence and spread of fluoroquinolone resistance not
only in Asia but also in many other parts of the world. Efforts
should be made to elucidate and alleviate the factors behind
this selection pressure. 
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